L Tselikas
Overview
Explore the profile of L Tselikas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deschamps F, Tselikas L, Cazzato R, Facchini G, Granata V, Bonnet B, et al.
Br J Radiol
. 2025 Feb;
PMID: 39900516
This review aims to analyse the safety and clinical efficacy in terms of pain relief and local tumour control, in patients with metastatic epidural spinal cord compression undergoing electrochemotherapy (ECT)....
2.
Peyraud F, Guegan J, Bodet D, Nafia I, Fontan L, Auzanneau C, et al.
Ann Oncol
. 2022 Jul;
33(10):1041-1051.
PMID: 35850444
Background: The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the systemic approach to cancer treatment. Most patients receiving ICIs, however, do not derive benefits. Therefore, it is crucial to...
3.
Moya-Plana A, Tselikas L, Lambotte O, Temam S, de Baere T, Deutsch E, et al.
ESMO Open
. 2022 Apr;
7(2):100451.
PMID: 35427841
Background: The coronavirus disease 2019 (COVID-19) pandemic has disrupted clinical practice, research and teaching. During peaks, virtual courses were implemented but these changes are poorly described, especially for oncology postgraduate...
4.
Chen J, Facchinetti F, Braye F, Yurchenko A, Bigot L, Ponce S, et al.
Ann Oncol
. 2022 Jan;
33(4):434-444.
PMID: 35066105
Background: The development of targeted agents, such as osimertinib for EGFR-mutated non-small-cell lung cancer (NSCLC), has drastically improved patient outcome, but tumor resistance eventually always occurs. In osimertinib-resistant NSCLC, the...
5.
Loriot Y, Marabelle A, Guegan J, Danlos F, Besse B, Chaput N, et al.
Ann Oncol
. 2021 Aug;
32(11):1381-1390.
PMID: 34416362
Background: Immune checkpoint blockers (ICBs) are now widely used in oncology. Most patients, however, do not derive benefit from these agents. Therefore, there is a crucial need to identify novel...
6.
Cornelis F, Barral M, Le Huec J, Deschamps F, de Baere T, Tselikas L
Cardiovasc Intervent Radiol
. 2021 Jan;
44(4):642-646.
PMID: 33388874
Purpose: To evaluate the feasibility and safety of percutaneous transpedicular fixation by PEEK polymer implants and cementoplasty for vertebral compression fracture (VCF). Materials And Methods: From February 2019 to December...
7.
Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F, et al.
Diagn Interv Imaging
. 2020 Oct;
102(1):19-26.
PMID: 33020025
Purpose: The purpose of this study was to compare efficacy and tolerance between radiofrequency ablation (RFA) and surgery for the treatment of oligometastatic lung disease. Materials And Methods: This retrospective...
8.
Barat M, Tselikas L, de Baere T, Gravel G, Yevich S, Delpla A, et al.
Eur J Radiol
. 2019 Oct;
121:108693.
PMID: 31594669
No abstract available.
9.
Barat M, Tselikas L, de Baere T, Gravel G, Yevich S, Delpla A, et al.
Eur J Radiol
. 2019 Sep;
119:108650.
PMID: 31525680
Purpose: To evaluate a strategy that used thermal-ablation of vertebral metastases (VM) to prevent vertebral related events (VRE) in patients with differentiated thyroid cancer (DTC). Methods: This single center study...
10.
Gustin P, Botticella A, Tselikas L, Mercier O, Le Pechoux C, Levy A
Rev Mal Respir
. 2019 Apr;
36(4):519-526.
PMID: 31010758
Lung cancer is the leading cause of cancer-related mortality and more than half of the cases are diagnosed at a metastatic stage. Major progress in terms of systemic treatments has...